Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic
Status:
Completed
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
Background: Up-to-date, there is no recognized effective treatment or vaccine for the
treatment of coronavirus disease (COVID-19) that emphasize urgency around distinctive
effective therapies. This study aims to evaluate the anti-parasitic medication efficacy
"Ivermectin" plus standard care (Azithromycin, Paracetamol, vitamin C, Zinc, Lactoferrin,
Acetylcystein, prophylactic or therapeutic anticoagulation if D-dimer > 1000 and/or steroids)
in the treatment of mild/moderate and severely ill cases with COVID 19 infection versus
Hydroxychloroquine plus standard care, as well as Ivermectin prophylaxis of health care and/
or household contacts.
Subject and methods: 600 subjects; 400 symptomatic confirmed COVID-19 patients and 200 health
care and household contacts distributed over 6 groups; Group I: 100 patients with
Mild/Moderate COVID-19 infection received a 4-days course of Ivermectin plus standard care;
Group II: 100 patients with mild/moderate COVID-19 infection received hydroxychlorquine plus
standard care; Group III: 100 patients with severe COVID-19 infection received Ivermectin
plus standard of care; Group IV: 100 patients with Severe COVID-19 infection received
hydroxychlorquine plus standard care. Routine laboratory investigations and real time-
polymerase chain reaction (rt-PCR) were reported before and after initiation of treatment.
Group V stick to personal protective equipment (PPE) plus Ivermectin, and Group VI stick to
PPE only and both groups were followed for two weeks.
Phase:
N/A
Details
Lead Sponsor:
Benha University
Treatments:
Acetaminophen Ascorbic Acid Azithromycin Fibrin fragment D Hydroxychloroquine Ivermectin Lactoferrin Vitamins Zinc